Compugen Ltd
CGEN- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001119774
In the last 90 days, Compugen Ltd insiders filed 0 open-market purchases and 1 sale; 83 institutions reported holding it in 13F filings for Q2 2026, worth $30.3M in total; ARK Invest is the only superinvestor holding it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Compugen Ltd insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 1 filing
- 1 insider, $4.69K in total
- Insiders trading
- 1
- Net value
- −$4.69K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Compugen Ltd, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Levine Zurit | SVP, Business Development | 47,375 | Jul 30, 2026 | 8 |
| Silberman David | Chief Financial Officer | 55,000 | Jul 30, 2026 | 1 |
| Ophir Eran | President and CEO | 11,375 | Jul 30, 2026 | 4 |
| Cohen-Dayag Anat | Director | – | Jul 30, 2026 | 1 |
| Perry Eran | Director | 17,500 | Jul 30, 2026 | 1 |
| Ferre Pierre | Chief Operating Officer | – | Jul 30, 2026 | 1 |
| Kredo Russo Sharon | SVP, Research & Discovery | 37,500 | Jul 30, 2026 | 1 |
| Livnat Savitzky Kinneret | Director | 20,850 | Jul 30, 2026 | 1 |
| Hukkelhoven Mathias | Director | 17,500 | Jul 30, 2026 | 1 |
| Halevy Gilead | Director | 18,907 | Jul 30, 2026 | 1 |
| Zweifach Sanford S | Director | 20,180 | Jul 30, 2026 | 1 |
| Mahler Michelle | Chief Medical Officer | 36,625 | Jul 30, 2026 | 1 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 13, 2026 (view filing)4:01 PM ET | Jul 9 | 4 days | Levine ZuritSVP, Business Development | SSale | −1.88K | $2.50 | −$4.69K | −6.0%29.4K after | 10b5-1 |
| Apr 27, 2026 (view filing) | Apr 24 | 3 days | Levine ZuritSVP, Business Development | SSale | −2.00K | $3.20 | −$6.40K | −6.4%29.4K after | 10b5-1 |
| Apr 27, 2026 (view filing) | Apr 24 | 3 days | Ophir EranPresident and CEO | SSale | −5.00K | $3.20 | −$16.0K | −30.5%11.4K after | 10b5-1 |
| Apr 15, 2026 (view filing) | Apr 14 | 1 day | Ophir EranPresident and CEO | SSale | −5.00K | $2.90 | −$14.5K | −30.5%11.4K after | 10b5-1 |
| Apr 15, 2026 (view filing) | Apr 14 | 1 day | Levine ZuritSVP, Business Development | SSale | −2.00K | $2.80 | −$5.60K | −6.4%29.4K after | 10b5-1 |
| Apr 15, 2026 (view filing) | Apr 10 | 5 days | Levine ZuritSVP, Business Development | SSale | −3.13K | $2.56 | −$8.00K | −9.6%29.4K after | Amended10b5-1 |
| Apr 9, 2026 (view filing) | Apr 7-8 | 2 days | Levine ZuritSVP, Business Development | SSale | −7.88K | $2.38 | −$18.8K | −21.1%29.4K after | 2 lots10b5-1 |
| Apr 3, 2026 (view filing) | Apr 1 | 2 days | Levine ZuritSVP, Business Development | SSale | −3.50K | $2.20 | −$7.70K | −10.6%29.4K after | 10b5-1 |
| Apr 3, 2026 (view filing) | Apr 1 | 2 days | Ophir EranPresident and CEO | SSale | −5.63K | $2.21 | −$12.4K | −33.1%11.4K after | 10b5-1 |
| Mar 30, 2026 (view filing) | Mar 26 | 4 days | Levine ZuritSVP, Business Development | SSale | −11.9K | $2.04 | −$24.2K | −28.8%29.4K after | 10b5-1 |